List of Excipients in Branded Drug YUTIQ

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alimera Sciences Inc	YUTIQ	fluocinolone acetonide	68611-180	POLYVINYL ALCOHOL
Alimera Sciences Inc	YUTIQ	fluocinolone acetonide	68611-180	WATER
EyePoint Pharmaceuticals Inc	YUTIQ	fluocinolone acetonide	71879-136	POLYVINYL ALCOHOL
EyePoint Pharmaceuticals Inc	YUTIQ	fluocinolone acetonide	71879-136	WATER

YUTIQ Excipient Strategy and Commercial Opportunities

Last updated: August 23, 2026

YUTIQ is a long-acting intravitreal fluocinolone acetonide implant for chronic noninfectious uveitis affecting the posterior segment of the eye. Its commercial differentiation comes less from conventional excipient innovation than from the integration of a low-dose steroid, polyvinyl alcohol drug matrix, polyimide reservoir, rate-controlling membrane and intravitreal delivery applicator. The product is designed to release fluocinolone acetonide for approximately 36 months after a single injection.[1]

The strongest commercial opportunities are in long-acting ocular delivery, implant manufacturing, formulation and device licensing, follow-on products for retinal inflammation, and differentiated products that reduce injection frequency. Generic substitution risk exists, but YUTIQ is more difficult to copy than a conventional ophthalmic solution because its performance depends on formulation, material selection, implant geometry, membrane permeability, sterilization and applicator design.

What is YUTIQ and how does its delivery system work?

YUTIQ contains 0.18 mg of fluocinolone acetonide in a non-bioerodible intravitreal implant. The FDA-approved indication is chronic noninfectious uveitis affecting the posterior segment of the eye.[1]

Attribute	YUTIQ
Active ingredient	Fluocinolone acetonide
Dose	0.18 mg
Dosage form	Intravitreal sustained-release implant
Route	Intravitreal injection
Release duration	Approximately 36 months
Indication	Chronic noninfectious uveitis affecting the posterior segment
Sponsor and manufacturer	EyePoint Pharmaceuticals
FDA approval	October 2018
Delivery platform	Durasert sustained-release technology
Primary commercial advantage	Three-year drug delivery from one office-based implant procedure

YUTIQ is delivered through a preloaded applicator. The implant is placed in the vitreous cavity and continuously releases fluocinolone acetonide. Its clinical value is based on reducing the need for repeated intravitreal steroid injections in a chronic disease that often requires prolonged anti-inflammatory treatment.

The implant differs from conventional ophthalmic products in which the excipient is primarily a solubilizer, buffer, preservative or viscosity modifier. In YUTIQ, the excipient and device architecture are part of the release-control system.

What excipients are used in YUTIQ?

The FDA prescribing information identifies polyvinyl alcohol as the inactive ingredient in YUTIQ’s drug formulation.[1] The implant also contains structural and rate-controlling components, including a polyimide tube and a permeable membrane within the Durasert system.

Component	Function in the product	Commercial significance
Fluocinolone acetonide	Anti-inflammatory active ingredient	Controls pharmacologic activity and dose
Polyvinyl alcohol	Drug-matrix excipient	Supports drug loading, physical integrity and controlled release
Polyimide reservoir	Implant structure	Provides a biocompatible, non-bioerodible housing
Rate-controlling membrane	Controls diffusion	Determines release kinetics over approximately three years
Applicator components	Enables intravitreal placement	Integrates the implant into a single-use delivery system

The exact commercial value of the excipient strategy lies in how these components work together. Polyvinyl alcohol is not simply an inactive filler. In a reservoir-based implant, the drug-polymer matrix affects loading uniformity, hydration, diffusion and long-term release behavior.

Why polyvinyl alcohol is commercially relevant

Polyvinyl alcohol is widely used in pharmaceutical products, but its use in YUTIQ is technically distinct from its use in ophthalmic drops or oral dosage forms. Relevant variables include:

• Polymer molecular weight and grade
• Degree of hydrolysis
• Residual moisture
• Drug-polymer compatibility
• Compression or loading conditions
• Long-term dimensional stability
• Sterilization effects
• Extractables and leachables
• Release-rate consistency

A substitute polymer would need to reproduce the release profile without changing implant size, dose uniformity, sterility, tissue response or shelf life. That creates barriers for both formulation suppliers and potential generic manufacturers.

How does YUTIQ’s excipient strategy control drug release?

YUTIQ uses a diffusion-controlled implant rather than a rapidly dissolving formulation. The drug is held in a reservoir and released through a permeable rate-controlling structure. The release rate is influenced by the drug’s solubility, polymer matrix, membrane properties, exposed surface area, implant geometry and manufacturing tolerances.

This architecture provides several commercial advantages:

1. It maintains drug exposure over a prolonged period.
2. It limits the need for repeated dosing.
3. It avoids preservatives in the vitreous formulation.
4. It allows the implant to use a very small total drug load.
5. It creates product performance that is difficult to replicate through excipient substitution alone.

The key development risk is dose dumping or release-rate drift. A small change in polymer processing, membrane thickness, pore structure or sterilization conditions can alter the in vitro release profile. For an implant intended to deliver drug for three years, stability testing must address both chemical degradation and physical changes in the drug reservoir.

What commercial opportunities exist for YUTIQ’s excipient platform?

Long-acting ophthalmic delivery

YUTIQ validates a commercial model for sustained delivery of low-dose corticosteroids in the eye. The same general platform can be evaluated for:

• Other corticosteroids
• Anti-inflammatory agents
• Immunomodulators
• Anti-infective combinations
• Drugs for retinal vascular disease
• Therapies for macular edema
• Treatments for chronic posterior-segment inflammation

The most attractive candidates are potent compounds that require continuous local exposure and have inadequate duration when administered as drops or periodic injections.

Platform licensing

The Durasert architecture may have value beyond YUTIQ. Platform licensing opportunities could include:

• Development rights for new active ingredients
• Regional rights for approved or investigational implants
• Co-development with ophthalmology companies
• Manufacturing partnerships for drug-device combination products
• Licensing of implant fabrication and assembly technology

Licensing economics would depend on whether the partner receives access to only the delivery technology or also formulation know-how, analytical methods, clinical data, regulatory files and manufacturing capacity.

Excipient and component supply

Specialty suppliers can target the YUTIQ supply chain through qualified materials and manufacturing services. The commercially relevant supply categories include:

• Pharmaceutical-grade polyvinyl alcohol
• Medical-grade polyimide tubing
• Rate-controlling membranes
• Drug loading and reservoir-filling equipment
• Micro-scale implant assembly
• Sterile packaging
• Extractables and leachables testing
• In vitro release testing
• Combination-product quality systems

Supplier qualification is likely to be demanding because material changes can affect product performance. A supplier with validated ocular biocompatibility data and a stable change-control history may have greater value than a lower-cost commodity polymer supplier.

Lifecycle management

Potential lifecycle strategies include:

• Alternative implant doses
• Shorter-duration implants for patients requiring titration
• Higher-dose implants for severe disease
• Modified applicators
• Reduced-gauge delivery systems
• Combination implants
• New indications involving chronic retinal inflammation
• Pediatric or special-population development
• Manufacturing changes that improve yield or reduce cost

Each strategy must address the balance between longer exposure and steroid-associated safety risks, particularly cataract formation, intraocular pressure elevation and glaucoma.

How does YUTIQ compare with Retisert and Iluvien?

YUTIQ competes within a small group of fluocinolone acetonide ocular implants, but the products have different doses, indications, delivery procedures and commercial positioning.

Product	Active ingredient	Dose	Duration	Main indication or use	Delivery profile
YUTIQ	Fluocinolone acetonide	0.18 mg	Approximately 36 months	Chronic noninfectious posterior-segment uveitis	Intravitreal office-based implant
Retisert	Fluocinolone acetonide	0.59 mg	Up to approximately 30 months	Chronic noninfectious posterior uveitis	Surgically implanted device
Iluvien	Fluocinolone acetonide	0.19 mg	Up to approximately 36 months	Diabetic macular edema in selected patients	Intravitreal injector

Retisert has a higher drug load and requires a surgical implantation procedure. YUTIQ is positioned as an office-based injectable implant for uveitis. Iluvien has a similar low-dose, long-duration concept but addresses diabetic macular edema and has a separate regulatory and commercial profile.[2][3]

The comparison demonstrates that excipient and device strategy cannot be separated from indication. The same active ingredient can support different products when dose, release kinetics, delivery method and patient population differ.

What patent and regulatory protections affect YUTIQ?

YUTIQ is a drug-device combination product. Its competitive protection may arise from several layers:

• Composition and drug-matrix claims
• Implant geometry
• Polymer and membrane configuration
• Release-rate specifications
• Applicator design
• Manufacturing methods
• Sterilization and packaging processes
• Method-of-use claims for posterior-segment uveitis
• Clinical and regulatory exclusivity

The commercial value of these rights depends on claim scope, expiration, terminal disclaimers, Orange Book listings, pediatric exclusivity and the ability to enforce claims against an ANDA applicant.

Orange Book status

YUTIQ’s regulatory pathway is more complex than that of a conventional ophthalmic generic. A follow-on applicant would need to address both the drug formulation and the delivery system. The FDA’s review would likely focus on:

• Active ingredient sameness
• Implant composition
• Dose and dimensions
• Release profile
• Sterility
• Applicator performance
• Local ocular safety
• Device equivalence or substitutability

A 505(j) applicant could challenge listed patents through Paragraph IV certification. The most important litigation risk would arise if a generic sponsor alleges that listed formulation, implant or method-of-use patents are invalid, unenforceable or not infringed.

Paragraph IV and generic entry risk

YUTIQ is not a biologic, so biosimilar regulation under the Public Health Service Act is not the primary follow-on pathway. The relevant risk is generic or complex generic entry under the Federal Food, Drug, and Cosmetic Act.

The likely generic-entry scenarios are:

Scenario	Timing risk	Commercial effect
No complex generic filing	Low near-term substitution risk	Continued branded control
Paragraph IV filing with litigation	Delayed and uncertain entry	Legal costs and potential settlement
Non-infringement or invalidity finding	High entry risk	Price erosion and account switching
Authorized generic or license	Managed erosion	Retained manufacturing or royalty economics
Competing implant with a different device	Moderate	May require separate clinical and regulatory pathway

Because the product’s clinical performance depends on long-term release, a generic applicant may face greater development cost than an applicant copying a solution, suspension or tablet. The barrier is not absolute. If the reference product’s critical quality attributes can be adequately characterized, an ANDA strategy remains possible.

What manufacturing and IP barriers protect YUTIQ?

The strongest barriers are likely to be technical rather than purely chemical.

Manufacturing barriers

YUTIQ requires control of:

• Micro-scale drug loading
• Polymer consistency
• Implant dimensions
• Membrane permeability
• Drug content uniformity
• Sterile assembly
• Applicator integration
• Long-term release testing

A manufacturing deviation may not be visible through short-term assay testing. The product therefore requires analytical methods capable of detecting changes in release rate and implant integrity.

Intellectual-property barriers

A robust patent estate for this type of product may combine broad platform claims with narrower implementation claims. The most valuable claims generally cover:

1. The implant structure.
2. The drug-polymer composition.
3. The membrane or diffusion pathway.
4. The release profile.
5. The delivery method.
6. The treatment of the approved disease.

Narrow claims can still have commercial value if they map directly to the marketed product and are difficult to design around. Broad claims are more valuable but face greater validity risk, particularly where prior art includes earlier fluocinolone implants or reservoir-based ocular delivery systems.

How strong is the commercial position of YUTIQ?

YUTIQ has four principal commercial strengths:

• A three-year dosing interval
• Office-based administration
• A focused indication with limited direct competition
• A delivery system that is harder to replicate than a standard ophthalmic formulation

Its commercial constraints include:

• Steroid-related safety monitoring
• Small addressable patient population relative to major retinal diseases
• Physician preference for injectable biologics or shorter-acting therapies
• Reimbursement and procedure economics
• Generic risk after patent and regulatory protection decline
• Manufacturing complexity

Revenue exposure is concentrated in a single product and a specialized ophthalmology market. That concentration increases the importance of continued indication expansion, manufacturing reliability and protection against complex generic entry.

What formulation and excipient opportunities exist beyond YUTIQ?

The most practical opportunities are not likely to come from replacing polyvinyl alcohol with a conventional excipient. They are more likely to involve redesigning the release system around a new drug or clinical use.

Near-term opportunity areas

• Lower-dose implants for patients at higher risk of steroid complications
• Implants with predictable six- to 12-month duration
• Dual-drug implants
• Implants for uveitis and macular edema
• Improved applicators for smaller-gauge injection
• Polymer systems with reduced manufacturing variability
• Drug reservoirs compatible with poorly soluble compounds

Higher-value development targets

A new product would have stronger commercial potential if it could reduce steroid exposure while preserving inflammation control. Other attractive attributes include a shorter procedure, lower injection force, improved implant visibility and easier management of adverse events.

For suppliers, the most defensible position is ownership of validated material grades, release testing methods and manufacturing know-how. Commodity excipient supply alone is less differentiated.

Key Takeaways

• YUTIQ uses a low-dose fluocinolone acetonide implant designed to release drug for approximately 36 months.
• Polyvinyl alcohol is the identified inactive ingredient in the drug formulation; the broader product also depends on polyimide and a rate-controlling membrane.
• The primary innovation is the integrated formulation-device system, not the excipient in isolation.
• Commercial opportunities include platform licensing, new ophthalmic implants, specialty material supply and lifecycle modifications.
• Generic risk is more complex than for a conventional ophthalmic product because an applicant must address formulation, implant performance, sterility and delivery-device equivalence.
• YUTIQ is not primarily exposed to biosimilar competition. The relevant follow-on threat is a complex generic or competing drug-device product.
• The main technical barriers are long-term release control, implant fabrication, sterile assembly and reproducible applicator performance.
• The main commercial risks are steroid safety, market concentration, reimbursement and eventual ANDA-based competition.

FAQs

Is polyvinyl alcohol the only excipient in YUTIQ?

Polyvinyl alcohol is the inactive ingredient identified in the FDA prescribing information. The marketed product also includes implant and delivery-system materials that control structure and drug release.[1]

Does YUTIQ contain a preservative?

YUTIQ is a solid intravitreal implant rather than a multidose ophthalmic solution. Its formulation does not rely on a conventional topical preservative system.

Can a generic manufacturer copy YUTIQ with the same excipient?

A generic manufacturer would need to demonstrate equivalence for the drug formulation and the implant delivery system. Using the same polyvinyl alcohol would not by itself establish equivalent release, sterility, device performance or clinical substitutability.

Is YUTIQ protected by biologic exclusivity?

No. Fluocinolone acetonide is a small-molecule corticosteroid, and YUTIQ is regulated as a drug-device combination rather than a biologic. Generic-drug and device-related protections are more relevant than biosimilar exclusivity.

What is the most valuable commercial asset in YUTIQ?

The most valuable asset is the integrated long-acting intravitreal delivery system, supported by formulation know-how, implant manufacturing capability, regulatory data and intellectual-property rights. Polyvinyl alcohol alone is a widely available material and is unlikely to provide meaningful standalone exclusivity.

References

1. U.S. Food and Drug Administration. (2018). YUTIQ (fluocinolone acetonide intravitreal implant) prescribing information. EyePoint Pharmaceuticals, Inc.

2. U.S. Food and Drug Administration. (2005). Retisert (fluocinolone acetonide intravitreal implant) prescribing information. Bausch & Lomb Incorporated.

3. U.S. Food and Drug Administration. (2014). Iluvien (fluocinolone acetonide intravitreal implant) prescribing information. Alimera Sciences, Inc.

4. U.S. Food and Drug Administration. (2022). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

5. EyePoint Pharmaceuticals, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.